Healthcare Industry News: psoriasis
News Release - March 6, 2007
Onset Therapeutics Launches Pharmaceutical Sales Force
Dedicated Sales Force to support Wound Care and Dermatology ProductsCUMBERLAND, R.I.--(HSMN NewsFeed)--Onset Therapeutics, a specialty pharmaceutical company that focuses on the development and commercialization of innovative, patent protected topical products for skin and wound related disorders, announced today that they have launched a dedicated sales force that will focus on the company's Wound Care and Dermatology product lines.
Onset Therapeutics deployed the field sales force in January 2007 and currently has 18 active territories nationwide, and plans to expand that number to 33 territories over the next 18 months. The sales team is supported by a team of inside sales professionals that focus on outreach efforts within the Company's key markets as well as on areas where the Company lacks field representation. In addition, a corporate account team is responsible for trade relations, managed care and key account sales while supporting the commercial efforts of the field force. The Onset sales force will promote the Company's rapidly-growing and innovative line of patent-pending, pharmaceutical products including Optase(TM) Gel, indicated to promote healing and the treatment of decubitus ulcers, varicose ulcers and dehiscent wounds; and Kerafoam(TM) Emollient Foam, indicated for softening, smoothing and removing rough scaling hyperkeratotic skin in conditions such as xerosis, ichthyosis, skin cracks and fissures, dermatitis, eczema, psoriasis, keratoses and calluses. The primary focus of the sales force is to target high prescribing dermatologists, long term care facilities, wound care clinics and hospitals.
Development and commercialization of novel therapies with clinical enhancements over existing products in the market is the core of Onset's strategy. With significant development capabilities that include product formulation and full cGMP manufacturing, the Company plans to commercialize its current pipeline of topical products within the wound care and dermatology markets over the next 3years. In addition, the company continues to evaluate acquisition, in-licensing, and co-promotion opportunities that are complementary to its customer base and therapeutic focus.
"The clinical and economic benefits associated with our currently marketed products were instrumental in helping to recruit talented, experienced pharmaceutical sales professionals," stated Michael Heffernan, President of Onset Therapeutics. "As we continue to broaden our product portfolio, we will continue to expand our sales force"
About Onset Therapeutics
Onset Therapeutics, a subsidiary of Collegium Pharmaceutical, Inc. (www.collegiumpharma.com) is a specialty pharmaceutical company dedicated to the development and commercialization of novel, patent protected topical products for the treatment of wounds and skin disorders. The Company is also actively pursuing in-licensing, co-development and co-promotion opportunities in its core therapeutic and customer segments. For more information, please visit the company's website at www.onsettx.com
Source: Onset Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
